Gene Mutations in Apical Hypertrophic Cardiomyopathy

Background— Nonobstructive hypertrophy localized to the cardiac apex is an uncommon morphological variant of hypertrophic cardiomyopathy (HCM) that often is further distinguished by distinct giant negative T waves and a benign clinical course. The genetic relationship between HCM with typical hypertrophic morphology versus isolated apical hypertrophy is incompletely understood. Methods and Results— Genetic cause was investigated in 15 probands with apical hypertrophy by DNA sequence analyses of 9 sarcomere protein genes and 3 other genes (GLA, PRKAG2, and LAMP2) implicated in idiopathic cardiac hypertrophy. Six sarcomere gene mutations were found in 7 samples; no samples contained mutations in GLA, PRKAG2, or LAMP2. Clinical evaluations demonstrated familial apical HCM in 4 probands, and in 3 probands disease-causing mutations were identified. Two families shared a cardiac actin Glu101Lys missense mutation; all members of both families with clinical manifestations of HCM (n=16) had apical hypertrophy. An essential light chain missense mutation Met149Val caused apical or midventricular segment HCM in another proband and 5 family members, but 6 other affected relatives had typical HCM morphologies. No other sarcomere gene mutations identified in the remaining probands caused apical HCM in other family members. Conclusions— Sarcomere protein gene mutations that cause apical hypertrophy rather than more common HCM morphologies reflect interactions among genetic etiology, background modifier genes, and/or hemodynamic factors. Only a limited number of sarcomere gene defects (eg, cardiac actin Glu101Lys) consistently produce apical HCM.

[1]  J. Seidman,et al.  Glycogen storage diseases presenting as hypertrophic cardiomyopathy. , 2005, The New England journal of medicine.

[2]  P. Elliott,et al.  Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[3]  M. Russo,et al.  Prevalence of Fabry Disease in Female Patients With Late-Onset Hypertrophic Cardiomyopathy , 2004, Circulation.

[4]  A. Børglum,et al.  Clinical and genetic characteristics of α cardiac actin gene mutations in hypertrophic cardiomyopathy , 2004, Journal of Medical Genetics.

[5]  B. Maron,et al.  Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States. , 2003, The American journal of cardiology.

[6]  Erik G. Ellsworth,et al.  Prevalence and Spectrum of Thin Filament Mutations in an Outpatient Referral Population With Hypertrophic Cardiomyopathy , 2003, Circulation.

[7]  M. Komajda,et al.  Hypertrophic Cardiomyopathy: Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy , 2003, Circulation.

[8]  S. Solomon,et al.  Assessment of Diastolic Function With Doppler Tissue Imaging to Predict Genotype in Preclinical Hypertrophic Cardiomyopathy , 2002, Circulation.

[9]  M. Eriksson,et al.  Long-term outcome in patients with apical hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[10]  Youbin Deng,et al.  Hypertrophic cardiomyopathy complicated by severe bradycardias: A pedigree report , 2002, Clinical cardiology.

[11]  J. Seidman,et al.  Sarcomere Protein Gene Mutations in Hypertrophic Cardiomyopathy of the Elderly , 2002, Circulation.

[12]  H. Wen,et al.  The Overall Pattern of Cardiac Contraction Depends on a Spatial Gradient of Myosin Regulatory Light Chain Phosphorylation , 2001, Cell.

[13]  H Niimura,et al.  Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. , 2001, Journal of the American College of Cardiology.

[14]  J. Seidman,et al.  The Genetic Basis for Cardiomyopathy from Mutation Identification to Mechanistic Paradigms , 2001, Cell.

[15]  L. Fananapazir,et al.  Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. , 2000, Journal of molecular and cellular cardiology.

[16]  H. Mabuchi,et al.  Clinical features of hypertrophic cardiomyopathy caused by a Lys183 deletion mutation in the cardiac troponin I gene. , 2000, Circulation.

[17]  A. Børglum,et al.  α-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy , 1999 .

[18]  A. Kisanuki,et al.  Patients with familial hypertrophic cardiomyopathy caused by a Phe110Ile missense mutation in the cardiac troponin T gene have variable cardiac morphologies and a favorable prognosis. , 1998, Circulation.

[19]  H Niimura,et al.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. , 1998, The New England journal of medicine.

[20]  M. Matsuzaki,et al.  Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy , 1997, Nature Genetics.

[21]  W. Rottbauer,et al.  Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy. Characterization Of cardiac transcript and protein. , 1997, The Journal of clinical investigation.

[22]  M. Yacoub,et al.  Codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy. , 1996, Circulation.

[23]  I. Rayment,et al.  Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle , 1996, Nature Genetics.

[24]  T. Imaizumi,et al.  Disappearance of giant negative T waves in patients with the Japanese form of apical hypertrophy. , 1995, Journal of the American College of Cardiology.

[25]  B. Maron,et al.  Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. , 1995, Journal of the American College of Cardiology.

[26]  K. Bailey,et al.  Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990. , 1995, Circulation.

[27]  Wigle Ed.  Novel insights into the clinical manifestations and treatment of hypertrophic cardiomyopathy. , 1995 .

[28]  F. Cosío,et al.  Familial apical hypertrophic cardiomyopathy. , 1988, The American journal of cardiology.

[29]  B. Maron,et al.  Apical Hypertrophic Cardiomyopathy: Clinical and Two-Dimensional Echocardiographic Assessment , 1987, Annals of internal medicine.

[30]  C. Tei,et al.  Asymmetric apical hypertrophy: ten years experience. , 1986, Postgraduate medical journal.

[31]  R. Bonow,et al.  Hypertrophic cardiomyopathy with ventricular septal hypertrophy localized to the apical region of the left ventricle (apical hypertrophic cardiomyopathy). , 1982, The American journal of cardiology.

[32]  B. Bainbridge,et al.  Genetics , 1981, Experientia.

[33]  T. Umeda,et al.  Hypertrophic nonobstructive cardiomyopathy with giant negative T waves (apical hypertrophy): ventriculographic and echocardiographic features in 30 patients. , 1979, The American journal of cardiology.

[34]  C. Tei,et al.  Giant T wave inversion as a manifestation of asymmetrical apical hypertrophy (AAH) of the left ventricle. Echocardiographic and ultrasono-cardiotomographic study. , 1976, Japanese heart journal.

[35]  A. Børglum,et al.  Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. , 1999, The Journal of clinical investigation.

[36]  E. Wigle.  Novel insights into the clinical manifestations and treatment of hypertrophic cardiomyopathy. , 1995, Current opinion in cardiology.